Home / Transcripts / Vinati Organics Limited (524200) · July 30, 2026

Vinati Organics Limited (524200) Earnings Call Transcript

July 30, 2026

BSE IN Materials Chemicals special 7 min

Earnings Call Speaker Segments

Unknown Analyst analyst
#1

With that, let's get into another earnings conversation. We do have Vinati Saraf Mutreja, Managing Director of Vinati Organics, joining in. The company's revenue in the first quarter grew by about 28%. The EBITDA, however, grew by just 7%, margins compressed and the net profit on the back of that grew by about 4.5%.

Unknown Analyst analyst
#2

Vinati, thank you so much for joining in. And that really is the first question because you've guided for 26% to 27% margins for FY '27. Now despite the delay in pricing or passing on the raw material price hike, are you confident of this 26% to 27% number? What kind of products will be margin drivers for you by the end of this year?

Vinati Mutreja executive
#3

You hear me?

Unknown Analyst analyst
#4

We can hear you.

Vinati Mutreja executive
#5

Okay. Okay. Great. Great. Sir, this quarter, we saw an improvement in the revenue. A lot of that has to -- a couple of factors have led to revenue growth. One is, of course, the rupee depreciation, 55% of our revenues do come from exports. Also, one significant thing is that the raw material prices increased a lot owing to the Middle East conflict, especially starting in March, April, May. And that -- some of it we were able to pass on as price increase. So that the volume growth we saw in certain products such as antioxidants and certain other new products, and that is what led to the revenue growth. Now consequently, the EBITDA margin did not grow by as much because most of it was just rupee depreciation as well as RMC increasing.

Unknown Analyst analyst
#6

Right, which is why the question. You've guided for 26% to 27% margins by the end of this year, and you're confident of that, right?

Vinati Mutreja executive
#7

Yes. I think that we should be able to maintain even this quarter, I believe the EBITDA margin is in that range of around 26%. And that is taking into account our entire product mix of ATBS, antioxidants, butylphenols as well as IBB and other derivatives.

Unknown Analyst analyst
#8

And in the second half of this year, how much would ATBS contribute in terms of extended capacity because you've increased capacity from, what, 20,000 tonnes per annum to about 60,000 tonnes, that, and even Veeral Organics starts in October 2026. So the second half will have a lot of these new products coming in.

Vinati Mutreja executive
#9

Yes. So ATBS, we have expanded capacity from 30,000 tonne to 50,000 tonne of the high quality, that is the metric. We do expect some demand recovery in ATBS starting October. Veeral Organics, like I had mentioned, the plant is under reengineering, which should get completed by December. And we expect more revenue coming in from January. So the second half should be better than the first half. And hence we expect overall, let's say, volume growth of maybe translating into revenue growth also of at least 15% this year and consequently, margin EBITDA growth as well.

Unknown Analyst analyst
#10

This particular financial year, how much would be the incremental revenue from the ATBS capacity and Veeral this year would do how much because on a steady state, you said could do about INR 120 crores, INR 130 crores.

Vinati Mutreja executive
#11

Yes. So Veeral Organics, the full potential on a steady state at 70%, 80% capacity utilization will be close to INR 400 crores, INR 500 crores. But just this year, starting FY '28, if I look at starting March '27, I would expect about INR 150 crores from Veeral Organics itself.

Unknown Analyst analyst
#12

Right. Okay. All right. Vinati, good to see you. Well, another debatable issue, which some analysts have written about, is about anisole. That's the key raw material for the new product line, I believe. And what we are seeing is that it is cheaper when it's imported in comparison to when it's produced in India. Could you tell us what is your take on the situation?

Vinati Mutreja executive
#13

See, yes, anisole, we are going to make from phenol and a lot of the -- and it will always be a make-or-buy decision. If it is cheaper to import it and buy it, then we will not make it, we will import it, buy it and then convert it into MEHQ as well as some other products that we are into. And if phenol prices remain low, then we will produce our own anisole. So I don't think that is any factor as such in revenue or EBITDA growth.

Unknown Analyst analyst
#14

All right. Just a final question before we let you go. You've embarked upon a serious CapEx as well, which is currently still underway. So if you could give us a sense on what your ROCE could decline to once the CapEx is at its peak? And by when does it start turning and what the peak could be and by when?

Vinati Mutreja executive
#15

So I think we are presently at a ROCE of about 15% to 16%. I think once we achieve full capacity utilization of our CapEx, one can expect improvement in the ROCE up to 20% after 2 years or 3 years. Having said that, we are making some new investments in downstream products in some of our forward integration products in the butylphenol as well as MEHQ as well as 4-methoxyacetophenone and a few isoamylene-based derivatives as well as adding a few antioxidants to our kitty.

Unknown Analyst analyst
#16

Antioxidants, you said would be how much? And you said that you are also considering new CapEx. How much would that be roughly in value terms?

Vinati Mutreja executive
#17

So actually, the marginal new CapEx in antioxidants will not be much. We will start achieving full capacity. We are already running at a very good run rate. The AO market has improved quite a bit in the last 3 months, and we are seeing realization improvement as well. And at the marginal CapEx, we will be able to add some new antioxidants and soon we will be reaching a 20% -- 15% to 20% ROCE in the additives business itself.

Unknown Analyst analyst
#18

Yes. ROCE doesn't go below this 15%, 16% in the near term as new capacities come on stream before they start to contribute positively, right?

Vinati Mutreja executive
#19

No, because actually most of the CapEx has already been done. So the only thing now ROCE can be improved as the utilization [indiscernible].

Unknown Analyst analyst
#20

Okay. All right. Thanks very much for joining us, Vinati. Appreciate your time here on CNBC-TV18 and good luck as you continue to execute.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vinati Organics Limited transcript - plus 252,000+ transcripts from 12,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Vinati Organics Limited earnings transcripts and 252,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $105 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.